Article
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Antimicrobial agents and chemotherapy - 1 Apr 2008
Malet Isabelle, Delelis Olivier, Valantin Marc-Antoine, Montes Brigitte, Soulie Cathia, Wirden Marc, Tchertanov Luba, Peytavin Gilles, Reynes Jacques, Mouscadet Jean-François, Katlama Christine, Calvez Vincent, Marcelin Anne-Geneviève
Abstract excerpt
Raltegravir (MK-0518) is a potent inhibitor of human immunodeficiency virus (HIV) integrase and is clinically effective against viruses resistant to other classes of antiretroviral agents. However, it can select mutations in the HIV integrase gene. Nine heavily pretreated patients who received salvage therapy including raltegravir and who subsequently developed virological failure under raltegravir therapy were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.